NCT03292133 2025-06-10A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung CancerMassachusetts General HospitalPhase 2 Terminated11 enrolled 10 charts
NCT02108964 2024-12-11A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesNovartisPhase 1/2 Completed225 enrolled 31 charts
NCT02335944 2023-06-18Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.NovartisPhase 1/2 Terminated177 enrolled 48 charts
NCT02323126 2022-02-28Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerNovartisPhase 2 Terminated64 enrolled 28 charts